MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
0.6091
+0.0237
+4.05%
After Hours: 0.5990 -0.0101 -1.66% 16:38 09/25 EDT
OPEN
0.5925
PREV CLOSE
0.5854
HIGH
0.6199
LOW
0.5787
VOLUME
161.24K
TURNOVER
--
52 WEEK HIGH
2.690
52 WEEK LOW
0.3151
MARKET CAP
20.27M
P/E (TTM)
-0.3856
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Remains a Buy on Jasper Therapeutics (JSPR)
TipRanks · 3d ago
Weekly Report: what happened at JSPR last week (0914-0918)?
Weekly Report · 4d ago
Jasper Therapeutics Appoints Regulatory, Clinical Executives For Pipeline Development; Stock Up
NASDAQ · 09/16 07:15
Press Release: Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Dow Jones · 09/15 20:05
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Barchart · 09/15 15:05
Weekly Report: what happened at JSPR last week (0907-0911)?
Weekly Report · 09/14 09:42
Weekly Report: what happened at JSPR last week (0831-0904)?
Weekly Report · 09/07 09:39
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/02 12:07
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.